Form 4: Thermo Fisher EVP Sells Shares Under 10b5-1 Plan

Frederick M. Lowery, Executive Vice President at Thermo Fisher Scientific, reported planned sales of common stock totaling 896.968 shares under a Rule 10b5-1 plan.

Summary

• Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific Inc. (TMO), reported transactions involving the company's common stock.
• On February 28, 2026, Lowery disposed of a total of 896.968 shares of common stock at a price of $521.11 per share.
• These dispositions were marked with transaction code 'F', indicating they were for the payment of exercise price or tax liability incident to the receipt, exercise, or vesting of a security.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following these transactions, Lowery directly beneficially owns 15,044.4044 shares of common stock.
• Lowery also indirectly beneficially owns 1,186.721 shares through a 401(k) plan, which acquired 0.037 shares between February 26, 2026, and February 28, 2026.
• An additional 5.036 shares are indirectly owned by a Limited Liability Company, with beneficial ownership disclaimed by the reporting person except to the extent of any pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine, pre-planned transactions, primarily for tax purposes, by an executive, which does not typically signal a change in company fundamentals or insider sentiment.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned, non-discretionary sales, which often reduces concerns about insider sentiment.
• A small acquisition of 0.037 shares occurred in the reporting person's 401(k) plan, indicating continued participation in the company's employee benefit program.

Negatives

• The disposition of shares, even if for tax purposes, reduces the direct equity stake of a key executive in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those under Rule 10b5-1 plans and for tax withholding purposes, are common across the life sciences and diagnostics industry. These types of filings typically do not reflect a change in the company's operational performance or strategic direction, nor do they usually indicate a shift in broader industry trends.

Comparison to Industry Standards

• StockSavvy.ai observes that the reported transactions are consistent with standard executive compensation practices in large, publicly traded companies within the healthcare and life sciences sector, where equity awards are a significant component of remuneration and often lead to tax-related sales upon vesting or exercise.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, providing a structured approach for insiders to trade company stock while mitigating concerns about the use of material non-public information, a practice widely adopted by executives at peer companies like Danaher Corporation and Agilent Technologies.

Related Party Transactions

• Acquisition of 0.037 shares of TMO common stock under the TMO 401(k) plan between February 26, 2026, and February 28, 2026.
• Indirect beneficial ownership of 5.036 shares by a Limited Liability Company, with the reporting person disclaiming beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine, pre-planned transactions by an executive and do not suggest a change in company performance or outlook.
• Employees: No direct impact on employees beyond the reporting person's own equity holdings.

Key Dates

Recommendation

A Form 4 filing detailing routine, pre-planned sales for tax purposes by an executive typically does not provide sufficient new information to warrant a change in investment recommendation. The transactions are non-discretionary and do not reflect a shift in the executive's confidence in the company's long-term prospects. Investors should continue to hold based on broader company fundamentals rather than this specific insider transaction.

Keywords

Thermo Fisher Scientific, TMO, Insider Trading, Form 4, Executive Vice President, Stock Sale, 10b5-1 Plan, Common Stock, Tax Withholding